New serological biomarkers of inflammatory bowel disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 33

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

581

HTML

3377

Tables (1-2)

125

Sum=4083

Sep 7, 2008 (publication date) through Apr 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Sep 7, 2008; 14(33): 5115-5124
Published online Sep 7, 2008. doi: 10.3748/wjg.14.5115

Table 2 A gene dosage effect: % positivity of antiglycan antibodies in CD patients carrying zero, one and two NOD2/CARD15 variants

	CD patients with 0 NOD2/CARD15 variant	CD patients with 1 NOD2/CARD15 variant	CD patients with 2 NOD2/CARD15 variants	P	Ref.
gASCA	51.50	64.20	72.30	< 0.0001	51
gASCA	41.60	64.60	67.50	< 0.0001	22
ALCA	34.90	42.10	46.70	< 0.04	51
AMCA	9.80	14.10	30	< 0.001	22
Any antiglycan	52.40	69.70	80	< 0.0001	22

Citation: Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol 2008; 14(33): 5115-5124
URL: https://www.wjgnet.com/1007-9327/full/v14/i33/5115.htm
DOI: https://dx.doi.org/10.3748/wjg.14.5115